Stocktoria
Takeda Pharmaceutical Company Limited 4502.T
JP · Tokyo Stock Exchange · XTKS · stock · Healthcare · website
Takeda Pharmaceutical Company Limited financials (annual)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ¥4.51T | ¥4.58T | ¥4.26T | ¥4.03T |
| Gross profit | ¥2.93T | ¥3.00T | ¥2.84T | ¥2.78T |
| R&D expense | ¥675.9B | ¥730.2B | ¥729.9B | ¥633.3B |
| SG&A expense | ¥1.08T | ¥1.10T | ¥1.05T | ¥997.3B |
| Operating income | ¥464.5B | ¥466.4B | ¥309.9B | ¥587.8B |
| Interest expense | ¥148.1B | ¥137.3B | ¥119.5B | ¥117.0B |
| Income tax | ¥9.8B | ¥66.9B | -¥91.4B | ¥58.1B |
| Net income | -¥152.4B | ¥107.9B | ¥144.1B | ¥317.0B |
| EPS (diluted) | ¥119.64 | ¥67.23 | ¥91.16 | ¥201.94 |
| Operating cash flow | ¥1.04T | ¥1.06T | ¥716.3B | ¥977.2B |
| Free cash flow | ¥626.8B | ¥677.6B | ¥235.6B | ¥343.5B |
| Cash & equivalents | ¥595.1B | ¥385.1B | ¥457.8B | ¥533.5B |
| Inventory | ¥1.40T | ¥1.22T | ¥1.21T | ¥986.5B |
| Goodwill | ¥5.81T | ¥5.32T | ¥5.41T | ¥4.79T |
| Total assets | ¥15.51T | ¥14.25T | ¥15.11T | ¥13.96T |
| Total debt | ¥4.88T | ¥4.52T | ¥4.84T | ¥4.38T |
| Total liabilities | ¥8.08T | ¥7.31T | ¥7.83T | ¥7.60T |
| Shareholders' equity | ¥7.43T | ¥6.94T | ¥7.27T | ¥6.35T |
| Share buybacks | ¥51.6B | ¥51.9B | ¥2.3B | ¥26.9B |
Growth · year-over-year · Revenue CAGR 3.8%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | -1.7% | +7.5% | +5.9% | — |
| Net income growth | -241.2% | -25.1% | -54.6% | — |
| EPS growth | +78.0% | -26.3% | -54.9% | — |
| Free cash flow growth | -7.5% | +187.6% | -31.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · JP · as of 2026-03-31. Figures in JPY. Facts plus Stocktoria's own computed scores — not investment advice.